Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Hospitalized within the last 36 hours.~2. Receiving any form of supplementary oxygen therapy at baseline.~3. Confirmed COVID-19 viral infection by RTPCR at screening.~4. Age:~   1. 18-65 years old, OR~  2. \>65 year-olds can be included after Data Monitoring Committee (DMC) approval~Key Exclusion Criteria:~1. Contraindications/hypersensitivity to P histicola or any of the capsule excipients~2. Patients with chronic hypoxia or underlying significant chronic respiratory disease (such as Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Bronchiectasis).~3. Admission to ICU at time of screening.~4. Mechanically ventilated, on continuous positive airway pressure (CPAP), or on non-invasive ventilation at the time of screening.~5. Patient is taking a systemic immunosuppressive agent such as, but not limited to, oral steroids, methotrexate, azathioprine, ciclosporin, or tacrolimus, unless these are given as part of COVID standard of care treatment.~6. Patient has a diagnosed primary immunodeficiency.~7. Patient has a diagnosis of HIV/AIDS~8. Patient has pre-existing known chronic kidney disease stage 4 or 5 or requiring renal replacement therapy (i.e. estimated glomerular filtration rate (eGFR) \<30ml/min/1.73m2)~9. Patient has pre-existing known significant liver disease with Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5.0 x upper limit of normal (ULN)~10. Patient has pre-existing known significant gastrointestinal tract disease expected to affect absorption within the small intestine (e.g. short bowel syndrome, inflammatory bowel disease affecting the small intestine, gastroparesis); or prior malabsorptive bariatric surgery that could interfere with GI delivery and transit time.~11. GI signs or symptoms equivalent to CTCAE v5.0, gastrointestinal disorders, grade 3 or 4 event.~12. Patient has pre-existing known substantially impaired cardiac function or pre-existing clinically significant cardiac diseases, including unstable angina or acute myocardial infarction ≤ 6 weeks prior to Screening.~13. Currently participating in an interventional clinical trial (observational studies allowed).~14. Moribund at time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EDP1815 (Type: EXPERIMENTAL): Patients will receive EDP1815 in addition to standard of care
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo in addition to standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).